Leap Therapeutics’ Success Tied to Partner NovaRock’s Commitment in Asian Markets
Company Announcements

Leap Therapeutics’ Success Tied to Partner NovaRock’s Commitment in Asian Markets

Leap Therapeutics (LPTX) has disclosed a new risk, in the Supply Chain category.

Leap Therapeutics’ business risk hinges significantly on NovaRock fulfilling its obligations under the NovaRock Agreement. With NovaRock entrusted to develop, manufacture, and commercialize FL-301 and FL-302 in key Asian markets, Leap Therapeutics’ reliance on NovaRock’s management of the manufacturing process and joint R&D activities is substantial. Leap Therapeutics’ limited influence over NovaRock’s performance poses a critical risk; any failure by NovaRock to meet its development responsibilities could severely impede the progression of FL-301 and FL-302, with potentially detrimental implications for Leap Therapeutics’ business prospects.

Overall, Wall Street has a Strong Buy consensus rating on LPTX stock based on 4 Buys.

To learn more about Leap Therapeutics’ risk factors, click here.

Related Articles
TheFlyLeap Therapeutics completes enrollment in Part B of DeFianCe study
TheFlyLeap Therapeutics reports Q2 EPS (52c), consensus (43c)
Catie PowersLPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App